Recently added

Ara mostrant els elements 261-265 d 1250

Development of a prognostic model to predict 90-day mortality in hospitalised cancer patients (PROMISE tool): a prospective observational study

Martin-Cullell, Berta; Vega Cano, Kreina Sharela; Recuero-Borau, Jordi; Gomez-Puerto, Diego; López-Valbuena, Daniel; Andurell Ferrrandiz, Laura; Berche, Roger; Ucha, Jose Maria; Rezqallah Arón , María Alejandra; Bueno, Sergio; Molina, Gaspar; Roca Herrera, Maria; Alonso, Ada; Peñuelas Saiz, Angeles; GOMEZ PARDO , PATRICIA; Serradell, Sònia; Mirallas, Oriol; Salva de Torres, Clara; Villacampa Javierre, Guillermo; Viaplana, Cristina; Hernando-Calvo, Alberto; Aguilar-Company, Juan; MUÑOZ COUSELO, EVA; Eremiev, Simeón; OAKNIN, ANA; Saura Manich, Cristina; Elez, Elena; Burgos Peláez, Rosa; GARRALDA, Elena; Tabernero, Josep; Dienstmann, Rodrigo; Carles, Joan; Palmas, Fiorella; Pedrola Gómez, Anna; Navarro Garces, Victor; Macarulla, Teresa; FELIP, ENRIQUETA; MARTINEZ-MARTI, ALEX (Elsevier, 2024-11)
Long-term survival following anti-PD-(L)1 monotherapy in advanced urothelial cancer and an assessment of potential prognostic clinical factors: a multicentre observational study

Stockem, Chantal F.; Einerhand, Sarah M. H.; Miras, Isabel; Salhi, Youssra; Pérez Calabuig, Esther; Bakaloudi, Dimitra Rafailia; Morales-Barrera, Rafael; Carles, Joan (Springer Nature, 2024-10-23)
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study

Fizazi, Karim; Matsubara, Nobuaki; Joung, Jae Young; Azad, Arun; Saad, Fred; De Giorgi, Ugo; Carles, Joan (Elsevier, 2024-12)
Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial

Harbeck, Nadia; Jerusalem, Guy; Müller, Volkmar; Niikura, Naoki; Viale, Giuseppe; Ciruelos, Eva; Escriva de Romani, Santiago (Nature Portfolio, 2024-12)
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study

Lim, Elgene; Jeselsohn, Rinath; Ma, Cynthia; Osborne, Cynthia; Jhaveri, Komal; Hamilton, Erika; Saura Manich, Cristina (American Society of Clinical Oncology, 2024-12-10)

Scientia. Dipòsit d'Informació Digital del Departament de Salut

VHIO - Articles científics: Recent submissions

Development of a prognostic model to predict 90-day mortality in hospitalised cancer patients (PROMISE tool): a prospective observational study

Long-term survival following anti-PD-(L)1 monotherapy in advanced urothelial cancer and an assessment of potential prognostic clinical factors: a multicentre observational study

Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study

Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial

Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study

Scientia. Dipòsit d'Informació Digital del Departament de Salut

VHIO - Articles científics: Recent submissions

Development of a prognostic model to predict 90-day mortality in hospitalised cancer patients (PROMISE tool): a prospective observational study ﻿

Long-term survival following anti-PD-(L)1 monotherapy in advanced urothelial cancer and an assessment of potential prognostic clinical factors: a multicentre observational study ﻿

Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study ﻿

Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial ﻿

Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study ﻿

Development of a prognostic model to predict 90-day mortality in hospitalised cancer patients (PROMISE tool): a prospective observational study

Long-term survival following anti-PD-(L)1 monotherapy in advanced urothelial cancer and an assessment of potential prognostic clinical factors: a multicentre observational study

Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study

Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial

Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study